REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization

Inclusion Criteria:

1. Male and female patients of any ethnic origin ≥18 years old at index date;

2. Patients with a diagnosis of epilepsy with uncontrolled focal-onset seizures despitethe previous treatment with from 2 to 5 ASMs who started treatment with cenobamateat index date;

3. Patients presenting at least 1 seizure a month in the last 6 months prior to indexdate;

4. Patients with at least 6 months of data coverage in the medical records prior to theindex date;

5. Patients with at least 12 months of data in the medical records after index date (with a maximum interval between data of 6 months).

6. Patients who give the consent to the processing of personal data according to theGeneral Data Protection Regulation (GDPR) and/or other applicable local regulation.

Exclusion Criteria:

1. Patients who meet any of the contraindications to the administration of adjunctiveASMs according to their approved SmPC;

2. Patients who started cenobamate within an EAP;

3. Progressive neurological disease, including degenerative CNS diseases and/orprogressive brain tumors;

4. Patients with specific syndrome (e.g. LGS and Dravet);

5. Pregnancy or lactation;

6. Patients without self-judgement ability;

7. Patients with substance and alcohol abuse or dependence (except for caffeine andnicotine);

8. Patients participating in any pharmacological or nonpharmacological interventionalstudy starting from 6 months before the index date.